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Abstract
Objectives: Recent epidemiologic studies have shown that obesity is associated with elevated blood concentrations of prothrombotic-
proinflammatory factors and markers of endothelial dysfunction such as fibrinogen, C-reactive protein (CRP), von Willebrand factor (vWF),
and homocysteine. We have assessed whether these markers are associated with percentage of body fat (BF), insulin sensitivity as well as
with leptin concentrations.
Design and methods: Twenty-five men aged 49.6  12.7 yr (mean  SD) underwent whole-body air displacement plethysmography
(Bod-Pod®) for estimating BF. Blood analyses for leptin and several other metabolic and cardiovascular markers were carried out.
Results: Obese subjects had higher levels as compared to controls of BF (37.5  5.1 vs. 26.0  6.6, p  0.01), fibrinogen (3.30  0.43
vs. 2.67  0.11, p  0.01), vWF (136.4  50.4% vs. 81.6  12.6%, p  0.05), and leptin (17.6  8.7 vs. 6.2  3.3, p  0.01), lower
concentrations of HDL-cholesterol (1.09  0.20 vs. 1.51  0.10, p  0.001) and lower QUICKI (1/[log(Ins0)  log(Glu0)]) (0.31  0.03
vs. 0.34  0.02, p  0.05). No significant changes were observed in CRP (5.7  3.4 vs. 3.8  1.6, p  0.327) and homocysteine (9.4 
4.2 vs. 8.3  0.9, p  0.749). A positive correlation was observed between BF and fibrinogen (r  0.67, p  0.0003). Plasma leptin
concentrations were correlated with fibrinogen (r  0.71, p  0.0001) and CRP (r  0.43, p  0.044). After adjustment for BF leptin
emerged as a significant predictor of fibrinogen (  0.47, p  0.023; R2  0.59, p  0.001). QUICKI was positively correlated with
HDL-cholesterol (r  0.59, p  0.010) and negatively with fibrinogen (r  0.53, p  0.025), CRP (r  0.52, p  0.028) and vWF
(r  0.56, p  0.013).
Conclusions: Increased BF and impaired insulin sensitivity are associated with increased concentrations of cardiovascular risk factors.
Leptin seems to be involved in this elevation and emerges as a predictor of circulating fibrinogen concentrations. © 2002 The Canadian
Society of Clinical Chemists. All rights reserved.
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1. Introduction
Obesity is the most prevalent nutritional disorder in in-
dustrialized countries and is a growing problem in develop-
ing countries [1,2]. It is defined by an excess of body fat
(BF) and is generally accompanied by insulin resistance [3].
Both situations lead to an increase in circulating cardiovas-
cular risk factors, which may be the origin of cardiovascular
diseases (CVD).
The mechanisms by which increased adiposity leads to
insulin resistance and CVD are poorly understood. Adi-
pose tissue has been previously considered to be a pas-
sive storage depot of energy. However, current evidence
shows that adipocytes play an active role in metabolism
through the secretion of hormones and cytokines in-
volved in whole-body energy homeostasis [4]. These
include leptin, adipsin, adiponectin, angiotensinogen, re-
sistin, plasminogen-activator inhibitor-1 (PAI-1), tumor
* Corresponding author. Tel.: 34-948-42-56-00 (ext. 6567); fax:
34-948-42-56-52.
E-mail address: jagomez@unav.es (J. Gomez-Ambrosi).
Clinical Biochemistry 35 (2002) 315–320
0009-9120/02/$ – see front matter © 2002 The Canadian Society of Clinical Chemists. All rights reserved.
PII: S0009-9120(02)00320-X
necrosis factor- (TNF-), and interleukin-6 (IL-6),
among others.
Leptin is a 16 kDa hormone secreted mainly by adipo-
cytes, although expression in placenta, fetal tissues, stom-
ach and other tissues has also been observed. Leptin informs
the brain about the size of the fat stores and has a wide
variety of central and peripheral actions, including effects
on reproduction, immune system, blood pressure, and an-
giogenesis [5].
Recent evidence suggests that leptin may be involved in
the development of CVD. Leptin has been associated with
impaired fibrinolysis [6,7], hypertension [8] and calcifica-
tion of vascular cells [9]. In addition, plasma leptin concen-
trations are raised in patients with congestive heart failure
[10] and correlate with heart rate in heart transplant recip-
ients [11]. Moreover, some authors have proposed hyper-
leptinemia as a component of a metabolic syndrome of
cardiovascular risk [12] while others have shown that leptin
is an independent risk factor for coronary events in hyper-
cholesterolemic men [13].
The present study tests the hypothesis that the increase in
blood concentrations of several cardiovascular risk factors
in obese subjects could be related to high fat mass and high
concentrations of leptin. Therefore, the aim of this work was
to assess whether several cardiovascular risk factors are
associated with percentage of BF, insulin sensitivity, as well
as leptin concentrations.
2. Methods
2.1. Subjects
Patients were recruited from obese persons visiting the
Endocrinology Department at the University Clinic of Na-
varra for weight loss treatment and were otherwise healthy.
Sex- and age-matched healthy controls were recruited
among hospital staff. The study included 25 men aged
49.6  12.7 yr, represented by 20 obese patients and 5
nonobese controls. Nonobese subjects were defined as hav-
ing a body mass index (BMI) 30 kg/m2, whereas subjects
with a BMI of 30 or more were classified as obese. The
examinations and blood collections were carried out in the
morning after a 12-h fast. All participants gave written
informed consent to participate in the present study, which
was approved by the Hospital’s Ethical Committee.
2.2. Anthropometric measurements
Body weight and height were measured using standardized
procedures. BMI was calculated as weight in kg divided by the
square of height in meters. The 1998 clinical guidelines were
used to define obesity (BMI  30) [14]. Body fat was esti-
mated by air-displacement-plethysmography (Bod-Pod®, Life
Measurements, Concord, CA, USA) [15 to 17]. This method
has been reported to agree closely with the traditional gold
standard hydrodensitometry (underwater weighing). Further-
more, the Bod-Pod® has been shown to predict fat mass and
fat-free mass more accurately than dual-energy X-ray absorp-
tiometry and bioelectrical impedance [15–17].
2.3. Blood analyses
Serum glucose was analyzed by an automated analyzer
(Hitachi 717), with quantification being based on the enzy-
matic colorimetric reactions described by Trinder [18]. In-
sulin was measured by means of an enzyme-amplified
chemiluminescence assay (IMMULITE®, Diagnostic Prod-
ucts Corp., Los Angeles, CA, USA). Total cholesterol and
triglyceride concentrations were determined by enzymatic
spectrophotometric methods (Boehringer Mannheim,
Mannheim, Germany). High-density lipoprotein (HDL-cho-
lesterol) was quantified by a colorimetric method in a Beck-
man Synchron® CX analyzer (Beckman Instruments, Ltd.,
Bucks, UK). Low-density lipoprotein (LDL-cholesterol)
was calculated by the Friedewald formula [19].
Fibrinogen concentrations were determined according to
the method of Clauss [20] using a commercially available
kit (Hemoliance®, Instrumentation Laboratory, Barcelona,
Spain). Measurement of von Willebrand factor (vWF) an-
tigen was performed by a micro-latex immunoassay (Diag-
nostica Stago, Inc., Parsippany, NJ, USA). A standard curve
was prepared with a universal reference (NISBC 91/666)
and the results were expressed as percentage of the standard.
Intra-and inter-assay coefficients of variation were between
4.0% and 8.0%. The concentrations of C-reactive protein
(CRP) were analyzed by means of an immunoturbidimetric
assay (Boehringer Mannheim) after calibration with the
standard CRM 470. Homocysteine was determined apply-
ing a fluorescence polarization immunoassay (Axis Bio-
chemicals ASA, Oslo, Norway), using an IMx® analyzer
(Abbott Laboratories, Abbott Par, IL, USA). Leptin was
measured by a double-antibody RIA method (Linco Re-
search, Inc., St. Charles, MO, USA). Intra-and inter-assay
coefficients of variation were 5.0% and 4.5%, respectively.
2.4. Calculation of insulin sensitivity
Insulin sensitivity was calculated by using the quantita-
tive insulin sensitivity check index (QUICKI) [21]. This
index represents a simple accurate method for assessing
insulin sensitivity in humans and is defined as 1/(log[insu-
lin0] log[glucose0]). QUICKI has been shown to correlate
better than the homeostasis model assessment (HOMA)
with the minimal model index of insulin sensitivity (SIMM)
and the gold standard method, namely the hyperinsulinemic
isoglycemic glucose clamp (SIclamp).
2.5. Statistical analysis
Data are presented as mean  standard deviation (SD).
Differences between groups were analyzed by Mann-Whit-
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ney U tests. Pearson’s correlation coefficients (r) were com-
puted to explore the correlations between two variables.
Interrelationships were assessed using a multivariate regres-
sion analysis. The calculations were performed using the
SPSS/Windows version 9.0.1 statistical package (SPSS,
Chicago, IL, USA). A p value lower than 0.05 was consid-
ered statistically significant.
3. Results
Clinical characteristics of the patients are summarized
in Table 1. No statistically significant differences for age
were found between the groups. As expected, BF as well
as BMI were significantly higher (p  0.01) in the obese
subjects. No differences were found in circulating con-
centrations of glucose and insulin between the two
groups. However, the QUICKI index, a method for as-
sessing insulin sensitivity, was significantly reduced (p 
0.05) in the obese individuals. Although total as well as
LDL-cholesterol concentrations were higher in the obese
group, they did not reach statistical significance. Triglyc-
erides were significantly increased (p  0.01) and HDL-
cholesterol was significantly reduced (p  0.001) in the
obese group (Table 2).
Prothrombotic factors such as fibrinogen and vWF were
significantly increased (p  0.01 and p  0.05, respec-
tively) in the obese subjects. CRP, a marker of systemic
inflammation, although being 50% increased in the obese
group did not show significant differences. Concentrations
of homocysteine were similar in both groups. As expected,
leptin concentrations were significantly higher (p 0.01) in
the obese patients (Table 3).
To analyze the influence of BF, leptin, and insulin resis-
tance in the concentrations of the cardiovascular risk factors
studied, correlations and multivariate regression analysis
were performed. Circulating concentrations of fibrinogen
were positively correlated with BF (Fig. 1A). Furthermore,
a stronger correlation between fibrinogen and leptin con-
centrations was found (Fig. 1B). Although no statistical
correlation between BF and CRP was found (Fig. 2A), the
latter was positively correlated with leptin (Fig. 2B). The
QUICKI index was negatively correlated with fibrinogen,
CRP and vWF, and positively correlated with HDL-choles-
terol (Figs. 3 and 4).
To assess the importance of the correlation of leptin
with both fibrinogen and CRP and to discard the potential
underlying effect of increased BF, a multiple linear re-
gression analysis was carried out, with both fibrinogen
and CRP as dependent variables and leptin and BF as
independent variables. Leptin emerged as a significant
predictor of fibrinogen concentrations after adjustment
for BF (  0.47, p  0.023; R2  0.59, p  0.001)
contributing to 55% of its variability. However, this was
not the case with CRP, whose correlation with leptin
disappeared after correction for BF.
Table 1
Characteristics of the obese and non-obese subjects
Obese
(n  20)
Non-obese
(n  5)
pa
Age (years) 47.8  13.3 56.8 7.6 0.1531
Body fat (%) 37.5  5.2 26.0 6.6 0.0022
BMI (kg/m2) 35.1  4.8 25.4 3.4 0.0014
Glucose (mmol/L) 6.1  2.5 5.3 0.5 0.8364
Insulin (pmol/L) 130.6 92.6 71.0 43.8 0.0604
QUICKI 0.31  0.03 0.34 0.02 0.0465
Data are mean  SD. BMI  body mass index; QUICKI  quantitative
insulin sensitivity check index.
a Mann-Whitney U-test comparing values between obese and non-obese
groups.
Table 2
Lipid profile of the obese and non-obese subjects
Obese
(n  20)
Non-obese
(n  5)
pa
Triglycerides (mmol/L) 2.50 2.36 0.93  0.17 0.0016
Total-Cholesterol (mmol/L) 5.99 1.41 5.05  1.00 0.0596
LDL-Cholesterol (mmol/L) 3.75 1.03 3.14  0.97 0.1259
HDL-Cholesterol (mmol/L) 1.09 0.20 1.51  0.10 0.0007
Data are mean  SD.
a Mann-Whitney U-test comparing values between obese and non-obese
groups.
Table 3
Cardiovascular risk factors of the obese and non-obese subjects
Obese
(n  20)
Non-obese
(n  5)
pa
Fibrinogen (g/L) 3.30 0.43 2.67 0.11 0.0067
von Willebrand factor (%) 136.4 50.4 81.6  12.6 0.0108
C-reactive protein (mg/L) 5.7 3.4 3.8 1.6 0.3269
Homocysteine (mol/L) 9.4  4.2 8.3 0.9 0.7489
Leptin (ng/mL) 17.6 8.7 6.2  3.3 0.0028
Data are mean  SD.
a Mann-Whitney U-test comparing values between obese and non-obese
groups.
Fig. 1. Correlations of BF (A) and leptin (B) with circulating concentra-
tions of fibrinogen of obese (F), or nonobese (E) patients. Pearson’s
correlation coefficient (r) and p values are indicated.
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4. Discussion
Growing scientific and medical data supports the evi-
dence that increased fat mass is associated with develop-
ment of CVD [22–24]. In line with this fact, the American
Heart Association included obesity as a major risk factor for
coronary heart disease in 1998 [25]. The present study
shows that increased BF and insulin resistance are related to
several markers of inflammation and endothelial dysfunc-
tion, and that leptin is probably involved in this association.
Our results confirm earlier data reporting increased fi-
brinogen and vWF concentrations in obesity [26–28], thus
reinforcing the observation that increased fat mass may
contribute to the development of CVD. In addition, fibrin-
ogen concentrations were strongly associated with BF. It is
well know that fibrinogen concentrations correlate with
BMI and BF [29,30], but the nature of this association is
unknown. Although correlations do not imply causality, it is
feasible that white adipose tissue plays a role in the regu-
lation of fibrinogen concentrations. This might be explained
by the increased production of IL-6 in adipose tissue of
obese patients [31], given the fact that this cytokine has
been shown to induce fibrinogen expression in the liver
[32]. If this is the case, however, a correlation between BF
and CRP, would have been expected since this marker has
also been shown to be regulated by IL-6 [33]. Another
possible explanation resides in the potential regulation of
fibrinogen concentrations by leptin through the induction of
hepatic expression of fibrinogen. In our study, this possibil-
ity is supported by the strong correlation observed between
circulating leptin and fibrinogen concentrations. In addition,
the main finding of this work is that blood leptin concen-
trations may be a predictor of blood fibrinogen concentra-
tions, given the fact that the association between them is
conserved after adjustment for BF. This possibility would
be in accordance with the proinflammatory role attributed to
leptin [34]. An alternative explanation is that leptin resis-
tance and not leptin itself increases fibrinogen concentra-
tions. This possibility is reinforced by the fact that obese
Zucker rats, which lack functional leptin receptors, and
hence are a model of leptin resistance, have higher concen-
trations of fibrinogen than normal rats [35]. Whether the
association of fibrinogen and leptin concentrations is due to
a direct effect of leptin or to leptin resistance requires
further experiments in which leptin resistance in humans is
assessed. The association between fibrinogen and leptin has
been previously observed in two studies [7,29]. However, in
both of them, the relation was not observed after adjustment
for BF or BMI. The present study suggests that increased
BF contributes to the development of a prothrombotic-
proinflammatory state and that leptin specifically correlates
with fibrinogen, suggesting that high leptin concentrations
lead to the achievement of this condition, therefore leading
to obesity-related disorders.
Despite a 50% increase in CRP concentrations in obese
patients compared to controls, no statistical significance was
reached. Several studies have shown that CRP is elevated in
human obesity [36,37] and that it is correlated with indica-
tors of adiposity [37–41]. These discrepancies may be ex-
plained taking into account several methodological aspects
of the present study. First, the limited sample size raises the
possibility of a lack of statistical strength. Second, several
factors such as smoking, hypertension, and treatment with
lipid-lowering or antihypertensive drugs may be confound-
ing factors. In addition, our population sample of obese
subjects may not be representative of central obesity, in
which CRP concentrations are clearly correlated with BF
[42]. However, in our study, CRP was significantly corre-
lated with leptin concentrations. This association, which
was not observed after adjustment for BF in multivariate
regression analysis, is in agreement with previous studies
[13,41,43] and suggests that, in addition to leptin, another
factor altered in obesity may be involved in the obesity-
induced increase in CRP.
The pronounced increase in vWF observed in obese
Fig. 2. Correlations of BF (A) and leptin (B) with circulating concentra-
tions of C-reactive protein of obese (F), or nonobese (E) patients. Pear-
son’s correlation coefficient (r) and p values are indicated.
Fig. 3. Correlations of fibrinogen concentrations (A) and C-reactive protein
(B) with the QUICKI of obese (F), or nonobese (E) patients. Pearson’s
correlation coefficient (r) and p values are indicated.
Fig. 4. Correlations of von Willebrand factor (A) and HDL-cholesterol (B)
with the QUICKI of obese (F), or nonobese (E) patients. Pearson’s
correlation coefficient (r) and p values are indicated.
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patients confirms that obesity has an adverse effect on the
endothelium [27,28]. However, vWF did not show a signif-
icant correlation with either BF or leptin. Therefore, the
increased vWF concentrations may be secondary to the
dyslipidemia or insulin resistance observed [44]. Our results
do not support an effect of increased adipose mass on
plasma homocysteine concentrations. These results are in
agreement with other published work [45,46], although
some authors have found a weak correlation between
plasma homocysteine and BMI [47].
Fibrinogen, CRP and vWF were negatively correlated
with the QUICKI index. Interestingly, HDL-cholesterol was
positively correlated with the QUICKI. Our data corrobo-
rate previous findings [48] and indicate that insulin resis-
tance may, by itself or as a consequence of increased fat
mass, induce endothelial dysfunction and inflammation.
Taken together, these results confirm the marked involve-
ment of insulin resistance associated to increased fat mass in
the development of CVD. Nevertheless, prospective studies
are needed to asses whether there is a simple association or
a causal relationship between insulin resistance and high
concentrations of fibrinogen, CRP and vWF and low con-
centrations of HDL-cholesterol.
In conclusion, these results indicate that men with high
levels of BF have increased circulating prothrombotic-
proinflammatory factors. Our work further strengthens the
possibility that this relation is, at least in part, mediated by
hyperleptinemia and insulin resistance. In addition, our re-
sults underline the role of leptin as an independent predictor
of plasma fibrinogen concentrations.
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